載入中
NASDAQHealthcareBiotechnology
最新資料
US$74.40
+US$1.24 · +1.69%
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
收盤時
US$74.40
+US$1.24 · +1.69%
盤後
US$74.40
US$0.00 · 0.00%
10月12日 下午5:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日內區間
目前US$74.40
52週區間
目前US$74.40
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
82
深度低估
情緒
52
多空交錯
風險
51
風險偏高
動能
40
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日內區間
目前US$74.40
52週區間
目前US$74.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.51億 USD | 1.83億 USD | 1744.7萬 USD | 2581.6萬 USD | 5702.7萬 USD |
| 銷貨成本 | 3068.4萬 USD | 1282.6萬 USD | 159.3萬 USD | 95.5萬 USD | 207.5萬 USD |
| 毛利 | 4.21億 USD | 1.7億 USD | 1585.4萬 USD | 2486.1萬 USD | 5495.2萬 USD |
| 研究與開發 | 6432.2萬 USD | 5338.6萬 USD | 5031.2萬 USD | 4262.4萬 USD | 4171.2萬 USD |
| 銷售、一般及管理費用 | 4.27億 USD | 2.37億 USD | 1.09億 USD | 4494.9萬 USD | 2539.7萬 USD |
| 營業費用 | 4.92億 USD | 2.91億 USD | 1.59億 USD | 8757.3萬 USD | 6710.9萬 USD |
| 利息收入 | 1574.7萬 USD | 1501.4萬 USD | 1033.7萬 USD | 349.9萬 USD | 3.6萬 USD |
| 利息支出 | 893.5萬 USD | 744.7萬 USD | 322.5萬 USD | 206.4萬 USD | — |
| 折舊和攤銷 | 181.6萬 USD | 122.5萬 USD | 87.7萬 USD | 32.6萬 USD | 31.2萬 USD |
| 營業利益 | −7096.9萬 USD | −1.21億 USD | −1.43億 USD | −6271.2萬 USD | −1215.7萬 USD |
| 淨利 | −6641.8萬 USD | −1.16億 USD | −1.36億 USD | −6209.1萬 USD | −1382.7萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI9647.38萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM7998.5萬0.10%787.4億 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF3419.15萬0.04%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO2828.02萬0.20%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB2343.95萬0.22%108.2億 USD0.44%US$204.26-1.08%
Invesco Pharmaceuticals ETFPJP1806.47萬3.29%5.48億 USD0.58%US$123.44+0.46%
Vanguard Russell 2000 ETFVTWO1787.3萬0.10%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA1475.85萬0.07%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBInvesco Pharmaceuticals ETFPJPVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
